Due to sponsored search results — a form of online advertising — the Ozempic formulation of semaglutide appears in Google searches for weight loss, despite not being FDA-approved for this indication. (NPR)
New analyses of an investigational high-dose semaglutide pill for obesity showed improvements in blood sugar control and cardiovascular risk factors across multiple categories of weight loss, said developer Novo Nordisk.
Eli Lilly expects the FDA to approve its oral obesity drug orforglipron, which showed weight losses of up to 11% in a recent trial, by March 2026. (Reuters)
Expect new dietary guidelines in December, said HHS Secretary Robert F. Kennedy Jr. (Reuters)
The Supreme Court reinstated a Trump administration policy prohibiting transgender Americans from listing their gender identity on their passports for now. (The Hill)
Some voters with fertility problems who don’t support Trump are nonetheless heartened by the steps he has taken to lower the costs of fertility medications. (New York Times)
In a recent Sermo survey of healthcare providers, 83% said they are diagnosing latent autoimmune diabetes in adults, known as type 1.5 diabetes, more often than they were 5 to 10 years ago.
Elevated HbA1c levels among general surgery patients were tied to an increase in postoperative complications, readmissions, and mortality in a retrospective cohort study. (JAMA Surgery)
The FDA cleared Tandem Mobi — the world’s smallest automated insulin delivery system, according to maker Tandem Diabetes Care — to be used with Android smartphones.
Gestational diabetes diagnosed earlier in pregnancy was linked to increased odds of autism spectrum disorder in girls, a case-control study suggested. (JAMA Network Open)
Central adiposity was associated with poor cognitive performance in early postmenopausal women, even in those with low cardiovascular risk, according to a secondary analysis of the KEEPS Cognitive and Affective Study. (Menopause)
